Cargando…

Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis

BACKGROUND: Non‐alcoholic steatohepatitis (NASH) is a severe form of non‐alcoholic fatty liver disease (NAFLD) characterised by liver fat accumulation, inflammation and progressive fibrosis. Emerging data indicate that genetic susceptibility increases risks of NAFLD, NASH and NASH‐related cirrhosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsson, Björn, Lindén, Daniel, Brolén, Gabriella, Liljeblad, Mathias, Bjursell, Mikael, Romeo, Stefano, Loomba, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318322/ https://www.ncbi.nlm.nih.gov/pubmed/32383295 http://dx.doi.org/10.1111/apt.15738

Ejemplares similares

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications
por: Jayakumar, Saumya, et al.
Publicado: (2019)

Review article: current and emerging therapies for the management of cirrhosis and its complications
por: Tapper, Elliot B., et al.
Publicado: (2022)

Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
por: Lindén, Daniel, et al.
Publicado: (2019)

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis
por: Davison, Beth A, et al.
Publicado: (2021)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
por: Brennan, Paul N, et al.
Publicado: (2022)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
por: Connelly, Margery A., et al.
Publicado: (2020)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
por: Sharpton, Suzanne R., et al.
Publicado: (2022)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

Diabetic Cardiomyopathy Modelling Using Induced Pluripotent Stem Cell Derived Cardiomyocytes: Recent Advances and Emerging Models
por: Granéli, Cecilia, et al.
Publicado: (2018)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
por: Federico, Alessandro, et al.
Publicado: (2021)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
por: Leow, Wei-Qiang, et al.
Publicado: (2020)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

‘Need-to-Know’ emergency medicine articles of 2014
por: Huis in ‘t Veld, Maite A, et al.
Publicado: (2015)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

Bearings in Hip Arthroplasty: Joint Registries vs Precision Medicine: Review Article
por: Pearson, Mark J., et al.
Publicado: (2016)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

The Role of Epigenetic Changes in the Progression of Alcoholic Steatohepatitis
por: Kim, Hyeong Geug, et al.
Publicado: (2021)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
por: Habig, Gregory, et al.
Publicado: (2021)

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021)

Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_994tvqhblmm2u2244ah2il5n7i